Biofisica Inc., an Atlanta-based company specializing in wound care therapy, today announced that it has obtained a commitment of $2.3 million in financing from investors. The funding will support Biofisica’s continued marketing efforts in the UK and ongoing planning initiatives in the U.S.
The round was led by Unilever Technology Ventures, Novartis Venture Funds, the ATDC Seed Capital Fund, as well as a number of private investors.
“We are very pleased that our investors continue to show a tremendous vote of confidence for the progress that we’re making with our business plan and the recognition that POSiFECT serves a critical need in the wound care market,” said Rafael Andino, founder of Biofisica.
POSiFECT is the first medical device available that combines two technologies – moist wound-care dressing and electrical stimulation – in a fully disposable, easy-to-use, sterile dressing that facilitates the normal healing process. Clinical research has shown that POSiFECT accelerates healing in difficult to heal or non-healing chronic wounds. The product launched last year in the UK and has since had excellent clinical response in a post market surveillance study. POSiFECT also has been approved for marketing in Canada. The product is not yet available in the U.S.
“We believe that Biofisica’s POSiFECT technology represents an innovative and effective approach to the treatment of chronic wounds,” said Dion Madsen, managing director of Physic Ventures, the General Partner for Unilever Technology Ventures. “Chronic wounds are currently poorly treated and this technology approach represents a very convenient and cost effective therapy that has the potential to improve the lives of millions of chronic wound care patients.”